• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.

作者信息

Girolomoni G, Feldman S R, Emery P, Ghil J, Keum J W, Cheong S Y, Hong E

机构信息

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A Stefani 1, 37126 Verona, Italy.

Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, U.S.A.

出版信息

Br J Dermatol. 2018 Mar;178(3):e215-e216. doi: 10.1111/bjd.16032. Epub 2018 Jan 30.

DOI:10.1111/bjd.16032
PMID:29023641
Abstract
摘要

相似文献

1
Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.一项III期研究中类风湿关节炎患者使用依那西普生物类似药SB4与参比依那西普的注射部位反应比较。
Br J Dermatol. 2018 Mar;178(3):e215-e216. doi: 10.1111/bjd.16032. Epub 2018 Jan 30.
2
Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis.预充式注射器和自动注射器在类风湿关节炎患者中使用 SB4（一种依那西普生物类似药）的可用性。
Adv Ther. 2019 Sep;36(9):2287-2295. doi: 10.1007/s12325-019-01027-z. Epub 2019 Aug 1.
3
Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort.原研药和生物类似药依那西普（SB4）在活动性类风湿关节炎中的疗效和安全性——一项全国真实世界队列研究的比较
Biologicals. 2019 Nov;62:27-32. doi: 10.1016/j.biologicals.2019.10.009. Epub 2019 Oct 24.
4
A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.一项在健康受试者中比较SB4与依那西普参比产品（恩利®）的随机I期药代动力学研究。
Br J Clin Pharmacol. 2016 Jul;82(1):64-73. doi: 10.1111/bcp.12929. Epub 2016 May 2.
5
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.一项III期随机、双盲、平行组研究，在尽管接受甲氨蝶呤治疗但仍患有活动性类风湿关节炎的患者中，将SB4与依那西普参比产品进行比较。
Ann Rheum Dis. 2017 Jan;76(1):51-57. doi: 10.1136/annrheumdis-2015-207588. Epub 2015 Jul 6.
6
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data.生物类似药和原研依那西普在类风湿关节炎患者中的疗效和安全性：真实世界数据。
Isr Med Assoc J. 2021 Jun;23(6):344-349.
7
Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.挪威常规临床实践中 SB4 和参照依那西普治疗类风湿关节炎患者的疗效和持久性。
Arthritis Care Res (Hoboken). 2023 Sep;75(9):1986-1995. doi: 10.1002/acr.25092. Epub 2023 Mar 7.
8
Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.转换为生物类似药英夫利昔单抗和依那西普治疗银屑病患者的有效性和安全性
Dermatol Ther. 2019 May;32(3):e12846. doi: 10.1111/dth.12846. Epub 2019 Feb 22.
9
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.免疫原性对肿瘤坏死因子抑制剂疗效和耐受性的影响：类风湿关节炎生物类似药研究的汇总分析。
Scand J Rheumatol. 2020 Sep;49(5):361-370. doi: 10.1080/03009742.2020.1732458. Epub 2020 May 29.
10
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.是否切换：全国强制性从原研药切换至生物类似药依那西普的指南结果。DANBIO 登记处 2061 例炎性关节炎患者的 1 年治疗结果。
Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.

引用本文的文献

1
A chemoenzymatic method for simultaneous profiling N- and O-glycans on glycoproteins using one-pot format.一种酶化学方法，用于使用一锅格式同时分析糖蛋白上的 N- 和 O-聚糖。
Cell Rep Methods. 2024 Aug 19;4(8):100834. doi: 10.1016/j.crmeth.2024.100834. Epub 2024 Aug 7.
2
Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.1024例类风湿关节炎患者从原研依那西普转换为依那西普生物类似药后的结局：英国风湿病学会生物制剂注册登记处类风湿关节炎匹配分析
Rheumatology (Oxford). 2024 Aug 1;63(8):2082-2092. doi: 10.1093/rheumatology/kead470.
3
Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.
依那西普原研药与依那西普生物类似药治疗类风湿关节炎作为一线生物制剂的比较：来自 BSRBR-RA 的结果。
Rheumatology (Oxford). 2023 Dec 1;62(12):3849-3857. doi: 10.1093/rheumatology/kead127.
4
Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data.韩国依那西普生物类似药SB4用于治疗风湿性疾病的安全性和有效性：真实世界上市后监测数据
Rheumatol Ther. 2023 Apr;10(2):329-341. doi: 10.1007/s40744-022-00515-z. Epub 2022 Dec 8.
5
An etanercept O-glycovariant with enhanced potency.一种具有增强效力的依那西普O-糖变体。
Mol Ther Methods Clin Dev. 2022 Mar 3;25:124-135. doi: 10.1016/j.omtm.2022.03.002. eCollection 2022 Jun 9.
6
Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.从依那西普转换为生物类似药SB4后的疗效和药物留存率：一项真实世界长期研究
J Clin Med. 2022 Jan 26;11(3):621. doi: 10.3390/jcm11030621.
7
Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review.皮下注射生物制剂后注射部位疼痛的理解与减轻：一项叙述性综述
Rheumatol Ther. 2020 Dec;7(4):741-757. doi: 10.1007/s40744-020-00245-0. Epub 2020 Nov 18.
8
The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.从原研依那西普转换为SB4：来自关节炎症性疾病治疗耐受性和持续性真实生活经验的数据。
Ther Adv Musculoskelet Dis. 2020 Oct 13;12:1759720X20964031. doi: 10.1177/1759720X20964031. eCollection 2020.
9
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.SB4 和 SB2、依那西普和英夫利昔单抗生物类似药的批间一致性。
BioDrugs. 2020 Apr;34(2):225-233. doi: 10.1007/s40259-019-00402-0.
10
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.生物类似药治疗风湿性疾病、斑块型银屑病和炎症性肠病的免疫原性：临床试验和监管文件的综述。
BioDrugs. 2020 Feb;34(1):27-37. doi: 10.1007/s40259-019-00394-x.